| pubmed-article:1330318 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C0149931 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C0443315 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C0075632 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C1304680 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C1261512 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C0599724 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C0699795 | lld:lifeskim |
| pubmed-article:1330318 | lifeskim:mentions | umls-concept:C1512888 | lld:lifeskim |
| pubmed-article:1330318 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1330318 | pubmed:dateCreated | 1992-12-15 | lld:pubmed |
| pubmed-article:1330318 | pubmed:abstractText | The results of the very first large-scale placebo-controlled dose-response trial with the novel selective 5-hydroxytryptamine1-like (5HT1-like) receptor agonist sumatriptan are presented. We studied the efficacy and tolerability of subcutaneous injections of 1 mg, 2 mg and 3 mg of sumatriptan in alleviating migraine attacks in a double-blind, placebo-controlled, parallel-group, multicentre clinical trial. Six-hundred and ninety patients were randomized and 685 received study medication. At 30 min, reduction of headache severity to mild or none (primary efficacy endpoint) was achieved in 22% (95% CI: 15-28%) of placebo-treated patients and in 39% (CI: 31-46%) of patients treated with 1 mg sumatriptan, 44% (CI: 36-51%) treated with 2 mg sumatriptan and 55% (CI: 48-63%) treated with 3 mg sumatriptan. Differences from placebo were 17% (CI: 8-27%) for 1 mg sumatriptan, 22% (CI: 13-32%) for 2 mg sumatriptan and 34% (CI: 24-44%) for 3 mg sumatriptan (p < 0.001 for all three comparisons). Other migraine symptoms were also more effectively treated by sumatriptan than by placebo. Subsequently, an open-label 3 mg dose subcutaneous sumatriptan was given to partial or non-responders. Thirty minutes after this open dose the response rate to sumatriptan had improved to between 70 and 80%. Adverse events after sumatriptan were minor and short-lived. We conclude that subcutaneous sumatriptan is well tolerated in doses up to 3 + 3 mg and may rapidly abort migraine attacks. | lld:pubmed |
| pubmed-article:1330318 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1330318 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330318 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1330318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330318 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1330318 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1330318 | pubmed:issn | 0333-1024 | lld:pubmed |
| pubmed-article:1330318 | pubmed:author | pubmed-author:PilgrimA JAJ | lld:pubmed |
| pubmed-article:1330318 | pubmed:author | pubmed-author:FerraroM JMJ | lld:pubmed |
| pubmed-article:1330318 | pubmed:author | pubmed-author:VisserW HWH | lld:pubmed |
| pubmed-article:1330318 | pubmed:author | pubmed-author:BaylissE MEM | lld:pubmed |
| pubmed-article:1330318 | pubmed:author | pubmed-author:LudlowSS | lld:pubmed |
| pubmed-article:1330318 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1330318 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:1330318 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1330318 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1330318 | pubmed:pagination | 308-13 | lld:pubmed |
| pubmed-article:1330318 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:meshHeading | pubmed-meshheading:1330318-... | lld:pubmed |
| pubmed-article:1330318 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1330318 | pubmed:articleTitle | Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. | lld:pubmed |
| pubmed-article:1330318 | pubmed:affiliation | Department of Neurology, University Hospital Leiden, The Netherlands. | lld:pubmed |
| pubmed-article:1330318 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1330318 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1330318 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
